ImageneBio, Inc. Comprehensive Income
ImageneBio, Inc. (IMA) reported Comprehensive Income of -$10.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$10.21M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$10.72M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$6.92M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$24.69M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$45.29M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$36.61M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$67.45M.
- ImageneBio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$69.53M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.21M 10-Q · filed 2026-08-05 | -$20.93M 10-Q · filed 2026-08-05 | -$27.85M derived: sum of 3 quarters · filed 2026-08-05 | -$52.54M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$10.72M 10-Q · filed 2026-05-07 | -$17.64M derived: sum of 2 quarters · filed 2026-05-07 | -$42.33M derived: sum of 3 quarters · filed 2026-05-07 | -$49.93M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$31.60M derived: sum of 2 quarters · filed 2026-03-10 | -$39.20M derived: sum of 3 quarters · filed 2026-08-05 | -$45.29M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | -$24.69M 10-Q · filed 2025-11-12 | -$32.29M derived: sum of 2 quarters · filed 2026-08-05 | -$38.38M 10-Q · filed 2025-11-12 | -$43.13M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$7.60M 10-Q · filed 2026-08-05 | -$2.80M 10-Q · filed 2025-07-24 | -$13.69M 10-Q · filed 2026-08-05 | -$11.39M 10-Q · filed 2025-07-24 | -$18.44M derived: sum of 3 quarters · filed 2026-08-05 | -$21.62M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$6.09M 10-Q · filed 2026-05-07 | -$8.59M 10-Q · filed 2025-05-08 | -$10.84M derived: sum of 2 quarters · filed 2026-05-07 | -$14.02M derived: sum of 3 quarters · filed 2026-05-07 | -$27.79M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$7.93M derived: sum of 2 quarters · filed 2026-03-10 | -$21.70M derived: sum of 3 quarters · filed 2026-03-10 | -$36.61M 10-K · filed 2026-03-10 | -$49.12M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$3.18M 10-Q · filed 2025-11-12 | -$9.64M 10-Q · filed 2024-11-07 | -$16.95M derived: sum of 2 quarters · filed 2025-11-12 | -$31.85M 10-Q · filed 2025-11-12 | -$39.82M 10-Q · filed 2024-11-07 | -$51.84M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$13.77M 10-Q · filed 2025-07-24 | -$30.18M 10-Q · filed 2025-07-24 | -$48.66M derived: sum of 3 quarters · filed 2025-07-24 | -$65.84M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | -$16.41M 10-Q · filed 2025-05-08 | -$34.90M derived: sum of 2 quarters · filed 2025-05-08 | -$52.07M derived: sum of 3 quarters · filed 2025-05-08 | -$69.15M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$18.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$35.66M derived: sum of 2 quarters · filed 2025-03-06 | -$52.74M derived: sum of 3 quarters · filed 2025-03-06 | -$67.45M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$17.18M 10-Q · filed 2024-11-07 | -$34.26M derived: sum of 2 quarters · filed 2024-11-07 | -$48.97M 10-Q · filed 2024-11-07 | -$61.88M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$17.08M 10-Q · filed 2024-08-08 | -$31.03M 10-Q · filed 2024-08-08 | -$31.79M 10-Q · filed 2023-08-10 | -$44.71M derived: sum of 3 quarters · filed 2024-08-08 | -$62.12M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$13.95M 10-Q · filed 2024-05-13 | -$27.63M derived: sum of 2 quarters · filed 2024-05-13 | -$45.04M derived: sum of 3 quarters · filed 2024-05-13 | -$66.16M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$31.09M derived: sum of 2 quarters · filed 2024-03-12 | -$52.21M derived: sum of 3 quarters · filed 2024-03-12 | -$69.53M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$17.41M 10-Q · filed 2023-11-09 | -$77.00K 10-Q · filed 2022-11-07 | -$38.53M derived: sum of 2 quarters · filed 2023-11-09 | -$55.85M 10-Q · filed 2023-11-09 | -$1.18M 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | -$21.12M 10-Q · filed 2023-08-10 | -$626.00K 10-Q · filed 2022-08-11 | -$38.43M 10-Q · filed 2023-08-10 | -$1.10M 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | -$17.32M 10-Q · filed 2023-05-15 | -$478.00K 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | -$34.12M 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |